News
06-08-2011, 05:23 AM
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, presented Phase 2 efficacy results for NeuVax in combination with trastuzumab at the American Society of Clinical Oncology (ASCO) annual meeting.
More... (http://www.news-medical.net/news/20110608/Positive-results-from-RXis-NeuVax-trastuzumab-Phase-2-trial-on-breast-cancer-presented-at-ASCO.aspx)
More... (http://www.news-medical.net/news/20110608/Positive-results-from-RXis-NeuVax-trastuzumab-Phase-2-trial-on-breast-cancer-presented-at-ASCO.aspx)